Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

First biologic treatment approved for children with lupus in Europe

Oct. 31, 2019

Flex Pharma synthesizes voltage-gated sodium channel blockers

Oct. 29, 2019

Kangpu completes first-in-human study of KPG-818

Oct. 11, 2019

Preliminary data presented from phase I/II ASPIRO study of AT-132

Oct. 9, 2019

XBiotech initiates phase II study of bermekimab in systemic sclerosis

Oct. 3, 2019

New registrational study evaluates miransertib in Proteus syndrome and PROS

Oct. 2, 2019

TLC initiates phase III pivotal EXCELLENCE study of TLC-599

Oct. 2, 2019

Development and characterization of IRAK-4 inhibitors

Sep. 30, 2019

Inflazome begins first-in-human study of IZD-334 for CAPS

Sep. 27, 2019

Positive topline results presented from phase II STAR study of tolperisone

Sep. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...